Automated Cell And Gene Therapy Manufacturing Systems Market

According to Stratistics MRC, the Global Automated Cell and Gene Therapy Manufacturing Systems Market is accounted for $1.8 billion in 2026 and is expected to reach $7.9 billion by 2034 growing at a CAGR of 20.3% during the forecast period. The Automated Cell and Gene Therapy Manufacturing Systems Market encompasses advanced manufacturing solutions that integrate robotic automation, closed-system cell processing, bioreactors, and intelligent process monitoring to support scalable production of cell and gene therapies. Increasing demand for personalized treatments, expanding clinical pipelines, and growing investment in advanced therapy manufacturing are supporting market growth. Integration of automated cell expansion, genetic modification, and quality control technologies improves manufacturing consistency and operational efficiency. Growing commercialization of advanced therapeutic products creates opportunities for integrated manufacturing platforms.

Market Dynamics:

Driver:

Increasing demand for scalable and standardized cell and gene therapy manufacturing

Increasing demand for scalable and standardized cell and gene therapy manufacturing is driving market growth. Pharmaceutical and biotechnology companies are expanding production capabilities to support growing clinical pipelines and commercialization of advanced therapies. Conventional manual manufacturing processes involve extensive labor, operational complexity, and variability between production batches. Automated systems improve process consistency, reduce contamination risks, and support controlled manufacturing environments. Advancements in closed-system cell processing, automated bioreactors, and digital process monitoring further strengthen adoption across cell and gene therapy production facilities.

Restraint:

High capital investment and complex integration of automated manufacturing systems

High capital investment and complex integration of automated manufacturing systems restrain market growth. Cell and gene therapy manufacturing platforms require specialized equipment, validated processing workflows, and controlled production environments, increasing implementation expenses. Differences in therapeutic products, cell sources, and manufacturing protocols complicate standardization across facilities. Regulatory requirements for process validation, quality assurance, and manufacturing documentation create additional challenges. Limited availability of skilled personnel and difficulties integrating automated equipment with existing production infrastructure may further delay adoption among smaller biotechnology companies.

Opportunity:

Expansion of allogeneic therapies and decentralized cell therapy manufacturing

Expansion of allogeneic therapies and decentralized cell therapy manufacturing presents significant growth opportunities. Biotechnology companies are developing scalable manufacturing processes for off-the-shelf cell therapies that require consistent production and efficient batch processing. Automated closed-system platforms can support distributed manufacturing facilities and reduce dependence on centralized production infrastructure. Growing investment in modular manufacturing systems, robotic automation, and digital quality monitoring encourages innovation. Advancements in automated cell expansion, non-viral gene delivery, and integrated process analytics are expected to accelerate commercialization across advanced therapy manufacturing networks.

Threat:

Regulatory compliance risks and manufacturing process variability

Regulatory compliance risks and manufacturing process variability pose significant challenges to market development. Automated cell and gene therapy manufacturing systems must maintain product identity, purity, potency, and consistency across complex biological processes. Equipment failures, software errors, or inadequate process controls may affect therapeutic product quality and manufacturing continuity. Differences in regulatory expectations and evolving standards for advanced therapies can complicate platform validation. Competition from established manual and semi-automated manufacturing approaches, alongside uncertainty regarding therapy commercialization, may further restrict investment and adoption.

Covid-19 Impact:

The COVID-19 pandemic disrupted cell and gene therapy manufacturing through supply chain interruptions, laboratory restrictions, and delays in clinical development activities. Limited availability of specialized materials, manufacturing equipment, and skilled personnel affected production schedules and facility operations. However, the pandemic highlighted the importance of resilient biomanufacturing infrastructure and accelerated interest in automation, remote monitoring, and closed-system processing technologies. Growing investment in biotechnology manufacturing and digital production systems supported recovery. Post-pandemic emphasis on scalable and flexible therapeutic manufacturing has encouraged continued adoption of automated platforms.

The automated cell processing systems segment is expected to be the largest during the forecast period

The automated cell processing systems segment is expected to account for the largest market share during the forecast period due to widespread requirements for cell isolation, washing, concentration, and preparation across cell therapy manufacturing workflows. Pharmaceutical companies and biotechnology manufacturers increasingly adopt automated processing platforms to reduce manual handling and improve production consistency. Growing commercialization of autologous and gene-modified cell therapies supports equipment demand. Advancements in closed-system processing, integrated fluid handling, and standardized manufacturing protocols further strengthen segment growth across advanced therapy production facilities.

The integrated end-to-end manufacturing systems segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the integrated end-to-end manufacturing systems segment is predicted to witness the highest growth rate due to increasing demand for fully automated and scalable cell therapy production workflows. Integrated platforms combine cell isolation, activation, expansion, genetic modification, and final product processing within coordinated manufacturing environments. Growing investment in commercial-scale cell and gene therapy production encourages adoption. Advancements in robotic handling, digital process control, and modular manufacturing architectures are expected to improve operational efficiency and accelerate deployment across biotechnology manufacturing facilities.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to established biotechnology infrastructure, substantial pharmaceutical investment, and strong development of cell and gene therapies. The United States leads regional adoption through advanced therapy manufacturers, contract development organizations, and specialized research institutions. Growing investment in commercial manufacturing facilities and automated production technologies supports market expansion. Collaboration among biotechnology companies, equipment manufacturers, and research organizations further strengthens regional demand for integrated cell and gene therapy manufacturing systems.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding biotechnology manufacturing capabilities, increasing investment in advanced therapies, and growing adoption of automated production technologies. China, Japan, South Korea, and India are advancing cell therapy research and biomanufacturing infrastructure. Increasing demand for scalable production systems and standardized quality control encourages technology deployment. Government-supported biotechnology initiatives and partnerships among pharmaceutical companies, equipment manufacturers, and contract manufacturing organizations are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the Automated Cell and Gene Therapy Manufacturing Systems Market include Miltenyi Biotec B.V. & Co. KG, Thermo Fisher Scientific Inc., Cytiva, Sartorius AG, Terumo Blood and Cell Technologies, Cellares Corporation, Ori Biotech Ltd., Multiply Labs, Inc., Cellular Origins, ADVA Biotechnology Ltd., Orgenesis Inc., Fresenius Kabi AG, Bio-Techne Corporation, Wilson Wolf Manufacturing Corporation, Eppendorf SE, Hamilton Company, Beckman Coulter Life Sciences, and Lonza Group AG.

Key Developments:

In October 2026, Ori Biotech Ltd. announced that Catalent had joined its Preferred Partner Network, establishing Catalent's Princeton facility as a Center of Excellence for the IRO automated manufacturing platform. The collaboration supports autologous cell therapy process development and GMP manufacturing.

In September 2026, Cellares Corporation partnered with Seoul National University Hospital to evaluate automated manufacturing of gene-modified hematopoietic stem and progenitor cell therapies using its Cell Shuttle platform. The collaboration targets manufacturing development for a potential treatment of paroxysmal nocturnal hemoglobinuria.

In September 2025, Lonza Group AG's Cocoon automated cell therapy manufacturing platform received FDA Advanced Manufacturing Technology designation, supporting the development of standardized and scalable cell therapy manufacturing processes.

Product Types Covered:
• Integrated End-to-End Manufacturing Systems
• Automated Cell Processing Systems
• Automated Cell Expansion & Bioreactor Systems
• Automated Gene Delivery & Cell Engineering Systems
• Automated Quality Control & Analytical Systems
• Manufacturing Automation Software
• Other Product Types

Therapy Types Covered:
• Autologous Cell Therapies
• Allogeneic Cell Therapies
• Gene-Modified Cell Therapies
• In Vivo Gene Therapies
• Stem Cell-Based Therapies
• Other Therapy Types

Technologies Covered:
• Closed-System Cell Processing
• Robotic Process Automation
• Automated Bioreactor & Perfusion Technology
• Microfluidic Cell Processing
• Automated Viral Vector Manufacturing
• Automated Non-Viral Gene Delivery
• Artificial Intelligence & Process Analytics
• Other Technologies

Applications Covered:
• Cell Isolation & Selection
• Cell Activation & Expansion
• Genetic Modification & Transduction
• Viral Vector Production & Purification
• Cell Harvesting & Formulation
• Quality Control & Release Testing
• Cryopreservation & Final Product Processing
• Other Applications

End Users Covered:
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Academic & Research Institutions
• Hospitals & Cell Therapy Centers
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances